Posts in the “Featured Only Featured Only” category:

Remote Participation Enables Patients with ALK-Positive Lung Cancer from Across the Country to Participate in New Study of Treatment Resistance

Posted by Bradley Newton on January 24th, 2019 |

The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, and researchers from the Dana-Farber Cancer Institute are launching a novel nationwide […]

Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers

Posted by Bradley Newton on November 15th, 2018 |

The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help researchers better understand why patients living with epidermal growth factor receptor (EGFR) positive lung cancer develop resistance to treatment over time, or […]

Addario Lung Cancer Medical Institute Collaborates with Washington University on ctDNA Analysis in Early Stage Lung Cancer Study

Posted by Bradley Newton on June 1st, 2018 |

InVision® ctDNA liquid biopsy platform being explored to help inform the management of patients following surgery of curative intent. The Addario Lung Cancer Medical Institute (ALCMI)… Read More

Motivated Patients with ROS1 Cancer Initiate Global Research Study

Posted by Bradley Newton on February 21st, 2018 |

Global collaboration among data scientists, engineers, developers, coders, radiologists and physicians to end the world’s deadliest cancer. The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for […]

The Fight of Our Lives: Confronting the Unmet Need in Lung Cancer

Posted by Bradley Newton on February 11th, 2016 |

Medical advancements, over the past year, have been game changing for lung cancer patients. In 1971, President Richard Nixon declared war on cancer, and now, we finally have a war on lung cancer. In 2015, the FDA approved 7 new treatments for lung cancer patients, and 5 of these approvals came over a 2-month period.

Early Study Results Find High Proportion of Young Lung Cancer Patients With Targetable Mutations

Posted by Bradley Newton on September 22nd, 2015 |

The preliminary results showed that 76 percent of study subjects under 40 had druggable mutations.

Genomics of Young Lung Cancer and INHERIT Studies Accepted for Presentation at ASCO

Posted by Bradley Newton on May 13th, 2015 |

Two Addario Lung Cancer Medical Institute research studies funded in part by the Bonnie J. Addario Lung Cancer Foundation chosen for presentation at the May/June 2015 American Society of Clinical Oncology Annual Meeting

International Partnership to Address Lung Cancer Epidemic

Posted by Bradley Newton on February 10th, 2015 |

According to a recent study in the Annals of Oncology, lung cancer fatalities are set to overtake breast cancer deaths among European women for the first time this year. It is predicted lung cancer deaths for women in Europe will reach 14.24 per 100,000 of the population in 2015.

ALCMI Launches Genomics of Young Lung Cancer Study

Posted by Steven Young on February 5th, 2015 |

The Addario Lung Cancer Medical Institute (ALCMI) today launched a new study, the Genomics of Young Lung Cancer, to understand why lung cancer occurs in young adults, who quite often are athletic, never smokers and do not exhibit any of the known lung cancer genetic mutations.

Exosome Diagnostics & ALCMI Announce Collaboration on Sequencing Blood

Posted by Steven Young on December 8th, 2014 |

CAMBRIDGE, Mass. and LOS ANGELES, Calif., Jan. 9, 2015 – Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced a strategic collaboration with the Addario Lung Cancer Medical Institute (ALCMI) to accelerate the development of its lead plasma-based diagnostics in development for mutation detection and monitoring in patients with lung cancer. The […]